A rare and improbable mutation in a protein encoded by an influenza virus renders the virus defenseless against the body’s immune system. This University of Rochester Medical Center discovery could provide a new strategy for live influenza vaccines in the future.
A new approach to the live flu vaccine would be particularly advantageous right now after the Centers for Disease Control and Prevention stopped recommending use of the live attenuate flu vaccine, FluMist® earlier this year. Several studies found that the pain-free nasal spray, which was used in about one-third of young children in the U.S., offered no protection to that especially vulnerable population. The flu shot, on the other hand, performed well and the CDC recommends using this vaccine in place of FluMist®.
“There is a need to understand what’s happening with the existing live vaccine and potentially a need to develop a new one,” said David Topham, Ph.D., Marie Curran Wilson and Joseph Chamberlain Wilson Professor of Microbiology and Immunology at URMC and author of the study. “We proposed that the mutation we found could be used to create a live vaccine.”
The mutation weakens the flu virus by making the flu-encoded protein, called Non-Structural 1 (NS1), defunct. Flu virus needs NS1 to prevent interferon, the immune system’s front line against viruses, from alerting the host cell that it has been infected. Inhibiting interferon affords the virus time to multiply and spread before the immune system can mount an attack.
Most people have healthy interferon responses and would quickly and easily fend off this weakened mutant strain of flu, but, “this virus somehow managed to find the one person that had an interferon defect that allowed it to replicate,” said Topham.
The probability of this virus surviving and infecting a human is so low – it is as if Topham and lead study author, Marta Lopez de Diego, Ph.D., research assistant professor of Microbiology and Immunology, found a needle in a haystack. The pair isolated the mutated virus from a nasal swab of a single flu sufferer who happened to be among the small percentage of people with inadequate interferon responses. When they looked for the NS1 mutation in a national database, it showed up in just 0.03 percent of all flu strains reported.
This naturally-occurring “attenuating” flu mutation could provide a new way to make live flu vaccines, which contain viruses that are alive, but “attenuated”, or weakened, so the vaccine itself does not cause illness in humans. Topham and Lopez de Diego suspect their NS1 mutation could be a great way to prevent viruses in the live vaccine from infecting anyone who has normal interferon responses, which is most people.
The study, published online in the Journal of Virology, also highlights the importance of flu virus surveillance – conducting studies like Topham’s to see how the flu is changing, what flu mutations are circulating in humans and animals, and how those mutations affect virus function.
Topham believes health leaders are not doing enough of that research. “The influenza field is largely fixated on studying pandemic or potential pandemic viruses, but those viruses only infect a few dozen people every year whereas seasonal flu infects millions – and yet we don’t study human influenzas closely enough.”
In fact, the World Health Organization estimates 1 billion flu infections each year, causing 300,000 to 500,000 deaths.
Until recently, researchers believed that proteins like NS1 did not change much from strain to strain and season to season, but Topham’s study and others show that NS1 mutations occur naturally and can affect its ability to suppress immunity. Monitoring for these mutations in nature could help us produce better vaccines that save more lives.
The Latest on: Influenza
via Google News
The Latest on: Influenza
- Antigenic and amino acid sequence variations in the haemagglutinins of type A influenza viruses recently isolated from human subjectson October 13, 2021 at 8:48 am
Since 1978, influenza A viruses with different antigenic properties have been isolated in many countries, even though little influenza activity has been recorded. In the present paper, the antigenic ...
- Britain told to brace for an early flu season by top expert as fears grow 60,000 could die from influenza this winteron October 13, 2021 at 8:01 am
Britain is now in its flu season, although the NHS usually is not pounded by the disease until January. Experts suggest, however, that this year's wave could come earlier than expected.
- DOH: COVID-19 Far Deadlier than Influenzaon October 12, 2021 at 9:30 pm
Dr. Sarah Kemble, Hawaiʻi Department of Health state epidemiologist, released a statement today on mortality rates involving COVID-19 and influenza, saying COVID-19 was far deadlier than the flu ...
- Twindemic? Vermont doctors weigh in on influenza and COVID-19on October 12, 2021 at 4:08 pm
Health leaders in Vermont don’t have a crystal ball to forecast this year’s flu season. They say only time will tell, but the word twindemic is on their radar, as COVID-19 remains ...
- Even in Shadow of COVID-19, Influenza Poses Pandemic Threaton October 12, 2021 at 10:49 am
The ability of any infectious agent to maintain constant transmission enables it to be an ongoing threat to public health. Few pathogens have achieved greater success at ongoing transmission potential ...
- INFLUENZA MAP: See a breakdown of flu cases in Arkansas & Missourion October 12, 2021 at 8:24 am
The influenza bug is beginning to show up in Arkansas and Missouri. The Centers for Disease Control released its latest flu numbers. The CDC rated the spread of the flu as ‘minimal’ in Arkansas.
- Influenza Diagnostics Market by Product, Test Type, End-user and Region - Global Forecast to 2026on October 12, 2021 at 2:48 am
The "Influenza Diagnostics Market by Product (Test Kits, Instruments), Test Type (Traditional (RIDT, Viral Culture, Serological), Molecular (PCR, INAAT- NASBAT, TMABAS)), End User (Diagnostic ...
- Global Influenza Diagnostics Market (2021 to 2026) - Advancements in Genomic and Proteomic Technologies Presents Opportunitieson October 11, 2021 at 10:45 am
Test Type (Traditional (RIDT, Viral Culture, Serological), Molecular (PCR, INAAT- NASBAT, TMABAS)), End User (Diagnostic Laboratories, Hospitals, Clinics), Region-Global Forecast to 2026" report has ...
- Prior immunity to influenza, not SARS-CoV-2, prevents severe disease and mortalityon October 11, 2021 at 3:07 am
Researchers from the Israel Institute of Biological Research delineated the interplay between IAV and SARS CoV-2 infections.
via Bing News